Categories: News

Cohere Health adds Vori Health to its Digital Prior Authorization Ecosystem

BOSTON, June 2, 2021 /PRNewswire/ — Cohere Health, an emerging high growth digital health company, and Vori Health, a first-class, innovative medical provider for musculoskeletal care announced a partnership that will enable Vori users to access Cohere’s digital prior authorization solution, while adding Vori’s virtual and in-person musculoskeletal care, premium online content, and social community to Cohere’s solutions.

Under the arrangement, Cohere will offer its health plan and risk-bearing customers the ability to connect with Vori as a preferred musculoskeletal ecosystem partner accessed via Cohere’s digital prior authorization platform. Cohere’s customers will be able to activate Vori for patients and providers connected to Cohere via Cohere’s evidence-based clinical pathways, which can be configured by line of business and customized for self-funded employer solutions.

Through this partnership, Cohere and Vori are directly integrating health plans and risk-bearing entities with appropriate, evidence-based, comprehensive musculoskeletal care. Not only does this improve care access, but also maximizes the quadruple aims of improving the patient experience, population health outcomes, cost effectiveness, and the provider experience. With the support of Cohere’s digital prior authorization solution, Vori will be able to immediately confirm patient coverage and enroll patients with minimal delay into its fully integrated, virtual musculoskeletal care program. Collectively, these capabilities will improve adoption of evidence-based practices, as well as patient experience and outcomes for patients experiencing musculoskeletal pain and dysfunction.

“We’re excited to combine forces with a digital health innovator like Vori, who is focused on using technology to improve musculoskeletal care outcomes,” said Siva Namasivayam, CEO, Cohere Health. “Unfortunately, a significant amount of care in this sector is unnecessary after considering patient preferences, social determinants, and the lack of objective evidence in pathways, such as for low back pain. Cohere’s position as an outcomes-focused digital prior authorization solution can better connect patients to the kinds of services and technology that Vori has designed to deliver.”

Cohere Health’s AI-based, fully automated solutions are driving industry-best digital adoption (92% of users), as they significantly reduce provider abrasion and enable personalized guidance across the patient’s entire episode of care. These solutions are also reducing care delays (up to 90% instant determinations) and unnecessary costs. Cohere’s solutions fully support pending CMS and state regulatory requirements, including immediate auto-determination, review turnaround times, provider “greenlighting” and FHIR interoperability standards.

Vori expects the partnership to better coordinate primary care and specialist activity by integrating Vori’s care pathway content and high-quality services into Cohere’s digital prior authorization platform. The Cohere platform will also enable greenlighting of Vori providers who consistently meet quality standards, and will reduce administrative barriers that can prevent patients from easily accessing high quality care.

“At Vori Health, one of our main initiatives is to creatively engage patients and provide faster access to appropriate, evidence-based care,” said Ryan Grant, MD, Founder & CEO of Vori Health. “The evolution of healthcare has demonstrated the necessity for more integrated care options, and what’s unique about this partnership is that we’re creating a complete musculoskeletal ecosystem—virtual, in-person, and digital—for complete care between the patient, provider and payer.”

To learn more about how Cohere Health helps patients, physicians and payers work together, please visit www.coherehealth.com.

To learn more about Vori Health’s integrated virtual musculoskeletal care services, please visit www.vorihealth.com.

About Cohere Health
Cohere’s digital health plan solutions fundamentally transform utilization management in order to drive truly collaborative care journeys. Their solutions not only automate provider and payer preauthorization functions, but also generate clinical policy guidance that drives better care decisions without having to delay or deny care. Cohere then uses prior authorization as a trigger to engage plans, providers and patients in episode-based care paths that merge traditional utilization management, care management and patient engagement functions. Cohere’s solutions also fully support pending CMS and state regulatory requirements, including immediate auto-determination, review turnaround times and FHIR interoperability standards. For more information, visit www.coherehealth.com.    

About Vori Health
Vori Health is an all-inclusive medical and health provider practicing a holistic, integrated approach starting with musculoskeletal care. The organization offers full service physical medicine and rehabilitation care, sports medicine, physical therapy, prescriptions, imaging & lab ordering, health coaching, nutritional guidance, community support and premium instructional content. The team consists of carefully selected, board-certified physicians and licensed healthcare providers, and provides health services that are accessible at the click of a button from the comfort, convenience, and privacy of a patient’s home. Learn more at www.vorihealth.com.

Media Contact:
Christopher Currington
Amendola Communications for Cohere Health
314.799.1987
ccurrington@acmarketingpr.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/cohere-health-adds-vori-health-to-its-digital-prior-authorization-ecosystem-301303647.html

SOURCE Cohere Health

Staff

Recent Posts

BioHarvest Launches VINIA SuperFood Functional Tea Line

Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood…

21 minutes ago

Neurotech Innovator UNEEG Medical Receives FDA Breakthrough Device Designation Within Monitoring and Diagnostic of Epilepsy

The designation is a result of UNEEG's strong focus on developing novel disease management support…

21 minutes ago

Lexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC /…

21 minutes ago

S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization

CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio…

21 minutes ago

Acreage Provides Update on Corporate Transactions

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Acreage Holdings, Inc. ("Acreage" or…

21 minutes ago